Media About Us


  • 05 October 2016

    Raindrop Receives FDA Approval

    Raindrop Receives FDA Approval

    Maria Scott, MD / Ophthalmology Management

    This year, I celebrated my20th anniversary of laser vision correction. I first needed glasses for myopia when I was 12, but only wore them in emergencies because I didn't want to look “nerdy.” At age 16, I got gas permeable lenses, which I loved, and later, laser vision correction, because I hated wearing glasses.

  • 27 September 2016

    Two New Corneal Inlays Increase Options for Presbyopia

    Two New Corneal Inlays Increase Options for Presbyopia

    Roger F. Steinert, MD / MedScape

    Until recently, the go-to options for treating presbyopia were reading glasses, monovision with either a contact lens or laser vision correction, or multifocal intraocular lenses. Today we now have one more arrow in our quiver: the corneal inlay, which offers patients a safe, less invasive, and reversible alternative to laser vision correction and intraocular lenses.

  • 20 September 2016

    Allergan Buys Liver Drug Maker Tobira for Up to $1.7 Billion

    Allergan Buys Liver Drug Maker Tobira for Up to $1.7 Billion

    Doni Bloomfield / Bloomberg

    Allergan Plc agreed to buy Tobira Therapeutics Inc. for as much as $1.7 billion to gain a late-stage experimental drug to treat liver diseases, one of the most anticipated categories in biotechnology.

  • 20 September 2016

    Say what? Allergan just agreed to pay a 6X cash premium for Tobira and its troubled PhIII NASH drug

    John Carroll / ENDPOINTS

    A couple of months after a trial setback crushed Tobira’s share price, Allergan has swooped in to buy the company for $29.35 a share and up to $49.84 a share in contingent value rights if its late-stage NASH drug turns out to be a hit.

  • 20 September 2016

    Allergan to buy Tobira in push for NASH treatments

    Allergan to buy Tobira in push for NASH treatments

    Natalie Grover / Reuters

    Allergan Plc (AGN.N) said it would buy Tobira Therapeutics Inc (TBRA.O) in a deal worth up to $1.7 billion, about 19 times the company's current value, to get a leg up in the race to develop therapies for NASH, an incurable fatty liver disease.

  • 20 September 2016

    Acquisitive Allergan buys micro-cap NASH biotech Tobira months

    Acquisitive Allergan buys micro-cap NASH biotech Tobira months

    Ben Adams / Fierce Biotech

    On the back of a number of deals in recent months, mainly in dermatology and after dodging its own $100 billion-plus consumption by Pfizer ($PFE) this year, Allergan ($AGN) has snapped up tiny Tobira ($TBRA) and its struggling fatty liver disease candidate, along with the rest of its pipeline, for potentially $1.7 billion.

  • 16 September 2016

    No More Reading Glasses? New Implant May Help With Aging Eyes

    No More Reading Glasses? New Implant May Help With Aging Eyes

    NBC NEWS

    The Raindrop implant reshapes the cornea to correct nearsightedness. Cheri Eckstadt, of Minnesota, is about to become the first person in the nation to get the newly-approved FDA device.

  • 16 September 2016

    So long, reading glasses? New Raindrop eye implant could make them obsolete

    So long, reading glasses? New Raindrop eye implant could make them obsolete

    Today

    Thanks to a new eye implant called the Raindrop, a five-minute procedure could make reading glasses a thing of the past. NBC News medical contributor Dr. John Torres reports on the first patient to undergo the procedure since it received FDA approval.

  • 12 September 2016

    Pfizer goes local with Russian joint venture - Doing Business With Russia

    Pfizer goes local with Russian joint venture - Doing Business With Russia

    Kira Egorova / Doing Business With Russia

    The American pharmaceutical corporation is building a new facility south of Moscow to capitalize on support from government initiatives, which is also indicative of its commitment to the local market. 

  • 07 September 2016

    Pfizer goes local with Russian joint venture

    Pfizer goes local with Russian joint venture

    Kira Egorova / Russia Beyond the Headlines

    In July 2016, the U.S. pharmaceutical giant Pfizer became the first foreign company in its sector to localize its business in Russia with a Russian partner. Pfizer and the Russian-American company NovaMedica, whose shareholders include the Russian state-owned company Rusnano, decided to jointly invest in the construction of a plant in the Kaluga Region, 125 miles southwest of Moscow.